AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $207.67 billion and ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

AstraZeneca (NASDAQ:AZN) announced Friday that the U.S. FDA approved its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) with chemoimmunotherapy as a first-line option for ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell ...

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.